Defining an inflamed tumor immunophenotype in recurrent, metastatic squamous cell carcinoma of the head and neck

R/M SCCHN patients with an inflamed tumor immunophenotype demonstrate improved survival. Further prospective studies are needed to validate these findings and explore the use of immunophenotype to guide patient selection for immunotherapeutic approaches.